Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients
Introduction: Breast cancer is the most common malignancy in women, and it is the second leading cause of malignancy-related mortality in women after lung cancer. Locally advanced breast cancer is a clinically heterogeneous group with a broad spectrum. Neoadjuvant chemotherapy (NAC) is the standard...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2024-11-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: | https://istanbulmedicaljournal.org/articles/relationship-of-neoadjuvant-chemotherapy-efficacy-with-histopathologic-molecular-subtypes-in-breast-cancer-patients/doi/imj.galenos.2024.96266 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846149994269114368 |
|---|---|
| author | Çiğdem Yıldırım Fatih Teker İlker Nihat Ökten İlkay Gültürk Aydın Aytekin Alper Aytekin Latif Yılmaz Çiğdem Usul Afşar |
| author_facet | Çiğdem Yıldırım Fatih Teker İlker Nihat Ökten İlkay Gültürk Aydın Aytekin Alper Aytekin Latif Yılmaz Çiğdem Usul Afşar |
| author_sort | Çiğdem Yıldırım |
| collection | DOAJ |
| description | Introduction: Breast cancer is the most common malignancy in women, and it is the second leading cause of malignancy-related mortality in women after lung cancer. Locally advanced breast cancer is a clinically heterogeneous group with a broad spectrum. Neoadjuvant chemotherapy (NAC) is the standard treatment at this stage. The present study aimed to evaluate the efficacy of NAC in terms of histopathologic molecular subtypes.
Methods: The study included 183 patients receiving NAC. Patients were studied in three groups: Luminal tumors, human epidermal growth factor receptor-2 (HER-2)-positive tumors, and triple-negative tumors based on the expressed receptor status. In our retrospective review, we only examined pathological complete response (pCR) based on breast tumor shrinkage before and after chemotherapy. In this study, we evaluated factors affecting pathologic complete response in patients receiving NAC.
Results: According to breast cancer subtypes based on biopsy results, pCR developed in 8 of 20 patients with triple-negative tumors (40%), 24 of 61 patients with HER-2-positive tumors (39.3%), and 22 of 102 patients with luminal tumors (21.5%) (p=0.030). The pCR rate was available in 5 of 40 patients with lymphovascular invasion (LVI) (12.5%) and 49 of 143 patients without LVI (34.2%) (p=0.008). pCR was available in 1 of 16 patients with perineural invasion (PNI) (6.6%) and 53 of 168 patients without PNI (31.5%) (p=0.043). PCR was available in 2 of 25 patients with extracapsular lymph node invasion (8%) and in 52 of 158 patients without extracapsular lymph node invasion (32.9%) (p=0.011).
Conclusion: The NAC pCR rate of hormone-positive tumors was lower than that of hormone-negative tumors in breast cancer. This finding was related to the biological response of the tumor in heterogeneous breast cancer. |
| format | Article |
| id | doaj-art-e32a2ade1a874c5a91a60a3e9550ebf9 |
| institution | Kabale University |
| issn | 2619-9793 2148-094X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | İstanbul Medical Journal |
| spelling | doaj-art-e32a2ade1a874c5a91a60a3e9550ebf92024-11-29T08:04:31ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2024-11-0125427428010.4274/imj.galenos.2024.96266Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer PatientsÇiğdem Yıldırım0https://orcid.org/0000-0002-9439-5941Fatih Teker1https://orcid.org/0000-0003-4693-6587İlker Nihat Ökten2https://orcid.org/0000-0003-2360-3392İlkay Gültürk3https://orcid.org/0000-0003-1998-3150Aydın Aytekin4https://orcid.org/0000-0002-7001-3945Alper Aytekin5https://orcid.org/0000-0003-2872-5276Latif Yılmaz6https://orcid.org/0000-0003-2528-9691Çiğdem Usul Afşar7https://orcid.org/0000-0002-3764-7639University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Medical Oncology, İstanbul, TurkeyLiv Hospital, Clinic of Medical Oncology, Gaziantep, Turkeyİstanbul Oncology Hospital, Clinic of Medical Oncology, İstanbul, TurkeyUniversity of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Medical Oncology, İstanbul, TurkeyGaziantep University, Şahinbey Training and Research Hospital, Clinic of Medical Oncology, Gaziantep, TurkeyGaziantep University, Şahinbey Training and Research Hospital, Clinic of General Surgery, Gaziantep, TurkeyGaziantep University, Şahinbey Training and Research Hospital, Clinic of General Surgery, Gaziantep, TurkeyUniversity of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Medical Oncology, İstanbul, TurkeyIntroduction: Breast cancer is the most common malignancy in women, and it is the second leading cause of malignancy-related mortality in women after lung cancer. Locally advanced breast cancer is a clinically heterogeneous group with a broad spectrum. Neoadjuvant chemotherapy (NAC) is the standard treatment at this stage. The present study aimed to evaluate the efficacy of NAC in terms of histopathologic molecular subtypes. Methods: The study included 183 patients receiving NAC. Patients were studied in three groups: Luminal tumors, human epidermal growth factor receptor-2 (HER-2)-positive tumors, and triple-negative tumors based on the expressed receptor status. In our retrospective review, we only examined pathological complete response (pCR) based on breast tumor shrinkage before and after chemotherapy. In this study, we evaluated factors affecting pathologic complete response in patients receiving NAC. Results: According to breast cancer subtypes based on biopsy results, pCR developed in 8 of 20 patients with triple-negative tumors (40%), 24 of 61 patients with HER-2-positive tumors (39.3%), and 22 of 102 patients with luminal tumors (21.5%) (p=0.030). The pCR rate was available in 5 of 40 patients with lymphovascular invasion (LVI) (12.5%) and 49 of 143 patients without LVI (34.2%) (p=0.008). pCR was available in 1 of 16 patients with perineural invasion (PNI) (6.6%) and 53 of 168 patients without PNI (31.5%) (p=0.043). PCR was available in 2 of 25 patients with extracapsular lymph node invasion (8%) and in 52 of 158 patients without extracapsular lymph node invasion (32.9%) (p=0.011). Conclusion: The NAC pCR rate of hormone-positive tumors was lower than that of hormone-negative tumors in breast cancer. This finding was related to the biological response of the tumor in heterogeneous breast cancer.https://istanbulmedicaljournal.org/articles/relationship-of-neoadjuvant-chemotherapy-efficacy-with-histopathologic-molecular-subtypes-in-breast-cancer-patients/doi/imj.galenos.2024.96266breast cancerneoadjuvant chemotherapymolecular subtypepathological response |
| spellingShingle | Çiğdem Yıldırım Fatih Teker İlker Nihat Ökten İlkay Gültürk Aydın Aytekin Alper Aytekin Latif Yılmaz Çiğdem Usul Afşar Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients İstanbul Medical Journal breast cancer neoadjuvant chemotherapy molecular subtype pathological response |
| title | Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients |
| title_full | Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients |
| title_fullStr | Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients |
| title_full_unstemmed | Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients |
| title_short | Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients |
| title_sort | relationship of neoadjuvant chemotherapy efficacy with histopathologic molecular subtypes in breast cancer patients |
| topic | breast cancer neoadjuvant chemotherapy molecular subtype pathological response |
| url | https://istanbulmedicaljournal.org/articles/relationship-of-neoadjuvant-chemotherapy-efficacy-with-histopathologic-molecular-subtypes-in-breast-cancer-patients/doi/imj.galenos.2024.96266 |
| work_keys_str_mv | AT cigdemyıldırım relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT fatihteker relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT ilkernihatokten relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT ilkaygulturk relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT aydınaytekin relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT alperaytekin relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT latifyılmaz relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients AT cigdemusulafsar relationshipofneoadjuvantchemotherapyefficacywithhistopathologicmolecularsubtypesinbreastcancerpatients |